South Dakota Cannabis Legislation

HB1160 repeals South Dakota's medical marijuana oversight committee, impacting administrative oversight for patients and the public.

HB1065 revises the medical cannabis affirmative defense, impacting patient protections in South Dakota by clarifying legal use in prosecutions.

SB39 revises industrial hemp provisions, impacting South Dakota's hemp industry, farmers, and consumers of hemp-derived products.

SB42 increases penalties for possessing, delivering, or ingesting controlled substances, including cannabis, within South Dakota correctional facilities, impacting inmates and their visitors.

HB1099 reschedules FDA-approved crystalline psilocybin to Schedule IV in South Dakota, easing access for patients and potentially impacting future medical research and product availability.

HB1016 modifies South Dakota's controlled substances schedule, impacting patients and consumers by potentially altering access to or penalties for certain substances.